Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer

Fig. 1

ADAM12 expression is upregulated in claudin-low breast cancer cells and in subpopulations enriched for CSCs. a. Cell surface expression of ADAM12 protein in breast cancer cell lines was evaluated by flow cytometry. Red, anti-ADAM12 antibody staining; gray, isotype control antibody staining. b Total cellular expression of ADAM12 was analyzed by Western blotting after partial purification of ADAM12 on concanavalin A (conA) agarose, as described [42]. GAPDH in the input fractions shows comparable conA agarose loading for all cells. Arrow, the nascent full length ADAM12; arrowhead, the processed form lacking the N-terminal pro-domain. c CSC signature score versus ADAM12 mRNA expression in 51 breast cancer cell lines. The CSC signature scores were calculated based on ref. [22] and microarray expression data retrieved from GEO:GSE69017, as described in Methods. Cell lines analyzed in panels a and b are shown in red. d ADAM12 protein levels in total lysates of SUM159PT cells grown as attached monolayers or as mammospheres, analyzed by Western blotting. Arrow, the nascent full length ADAM12; arrowhead, the processed form lacking the N-terminal pro-domain; *, a non-specific band. Positive control represents ADAM12 after partial purification on conA agarose. e Cell surface expression of ADAM12 in SUM159PT cells treated for 6 days with DMSO (control) or with 10 nM paclitaxel (PTX), and then allowed to recover for 6 days without PTX, was examined by flow cytometry. The population of cells with the highest expression of ADAM12 is shown in red. FSC, forward scatter

Back to article page